

Lactose, Inhalation

1 Nonproprietary Names

None adopted.

2 Synonyms

InhaLac; inhalation lactose; *Lactohale*; *Respitose*.
For grades, see Tables I and II.

3 Chemical Name and CAS Registry Number

Inhalation lactose is lactose monohydrate, O-β-D-galactopyranosyl-(1→4)-α-D-glucopyranose monohydrate (see Lactose Monohydrate), or anhydrous lactose, O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranose, or a mixture of O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranose and O-β-D-galactopyranosyl-(1→4)-α-D-glucopyranose (see Lactose, Anhydrous).

CAS numbers for lactose monohydrate include [5989-81-1] (lactose monohydrate); [10039-26-6] (lactose monohydrate, cyclic), and [64044-51-5] (lactose monohydrate, open form). The CAS number for anhydrous lactose is [63-42-3].

4 Empirical Formula and Molecular Weight

$C_{12}H_{22}O_{11}$ 342.30 (for anhydrous)
 $C_{12}H_{22}O_{11} \cdot H_2O$ 360.31 (for monohydrate)

5 Structural Formula

See Lactose, Anhydrous; Lactose Monohydrate.

6 Functional Category

Dry powder inhaler carrier.

7 Applications in Pharmaceutical Formulation or Technology

Inhalation lactose is widely used as a carrier, diluent, and flow aid in dry powder inhalation formulations. Inhalation lactose of suitable particle size can also be used to prepare soft pellets of dry powder inhaler formulations.

See also Lactose, Anhydrous; Lactose Monohydrate.

8 Description

Lactose occurs as white to nearly white crystalline particles or powder. It is odorless and slightly sweet-tasting.

9 Pharmacopeial Specifications

See Lactose, Anhydrous; Lactose Monohydrate.

10 Typical Properties

Density (bulk) see Table I.

Density (tapped) see Table I.

Loss on drying see Table I.

Particle size distribution see Table II.

Surface area see Table I.

11 Stability and Storage Conditions

Inhalation lactose should be stored in a well-closed container in a cool, dry, odor-free place.

Table I: Typical physical properties of selected commercially available inhalation lactose.

Supplier/grade	Surface area (m ² /g)	Density (bulk) (g/cm ³)	Density (tapped) (g/cm ³)	Loss on drying (%)
DFE Pharma				
<i>Lactohale 100</i>	–	–	–	≤0.2
<i>Lactohale 200</i>	–	–	–	≤0.2
<i>Lactohale 300</i>	–	–	–	≤0.5
<i>Respitose ML001</i>	0.9	0.57	0.88	–
<i>Respitose ML006</i>	1.6	0.43	0.75	–
<i>Respitose SV003</i>	0.4	0.63	0.78	–
<i>Respitose SV010</i>	0.2	0.69	0.83	–
Meggle GmbH				
<i>InhaLac 70</i>	0.1	0.59	0.69	–
<i>InhaLac 120</i>	0.2	0.69	0.80	–
<i>InhaLac 230</i>	0.2	0.69	0.83	–
<i>InhaLac 250</i>	0.3	0.65	0.85	–
<i>InhaLac 400</i>	1.9	0.33	0.53	–

Table II: Typical particle size distribution of selected commercially available inhalation lactose.

Supplier/grade	d ₁₀ (μm)	d ₅₀ (μm)	d ₉₀ (μm)
DFE Pharma			
<i>Lactohale 100</i> ^(a)	45–65	125–145	200–250
<i>Lactohale 200</i> ^(a)	5–15	50–100	120–160
<i>Lactohale 201</i> ^(a)	3–6	20–25	50–60
<i>Lactohale 300</i> ^(b)	–	<5	≤10
<i>Respitose ML001</i> ^(b)	4	55	170
<i>Respitose ML006</i> ^(a)	2	17	45
<i>Respitose SV003</i> ^(b)	30	60	100
<i>Respitose SV010</i> ^(a)	50	105	175
Meggle GmbH			
<i>InhaLac 70</i>	120	210	300
<i>InhaLac 120</i>	90	130	180
<i>InhaLac 230</i>	45	100	140
<i>InhaLac 250</i>	20	60	100
<i>InhaLac 400</i>	1.29	8.40	28.20

(a) Sympatec laser diffraction.

(b) Malvern (wet) laser diffraction.

12 Incompatibilities

Lactose is a reducing sugar. Typical reactions include the Maillard reaction with either primary⁽¹⁾ or secondary amines.⁽²⁾

See also Lactose, Anhydrous; Lactose Monohydrate.

13 Method of Manufacture

Inhalation lactose is manufactured by milling, sieving, air classifying, micronizing and/or blending pharmaceutical grade lactose, typically in dedicated facilities with suitable equipment in place to